AR055360A1 - Inhibidores macrociclicos del virus de la hepatitis c - Google Patents
Inhibidores macrociclicos del virus de la hepatitis cInfo
- Publication number
- AR055360A1 AR055360A1 ARP060103305A ARP060103305A AR055360A1 AR 055360 A1 AR055360 A1 AR 055360A1 AR P060103305 A ARP060103305 A AR P060103305A AR P060103305 A ARP060103305 A AR P060103305A AR 055360 A1 AR055360 A1 AR 055360A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- het
- aryl
- optionally substituted
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
- C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Inhibidores de la replicacion del VHC de formula (1) y los N-oxidos, sales o estereoisomeros de los mismos, donde cada línea punteada (representada por ----) representa un doble enlace opcional; X es N, CH, y cuando X posee un doble enlace es C; R1 es -OR6, -NH-SO22-R7; R2 es hidrogeno y cuando X es C o CH, R2 también puede ser alquilo C1-6; R3 es hidrogeno, alquilo C1-6, alcoxi C1-6-alquilo C1-6, o cicloalquilo C3-7; ///n es 3, 4,,5 o 6; R4 y R5 de manera independiente entre si son hidrogeno, halo, hidroxi, nitro, ciano, carboxilo, alquilo C1-6, alcoxi C1-6, alcoxi C1-6, alquilcarbonilo C1-6, alcoxi C1-6-carbonilo, amino, azido, mercapto, alquiltio C1-6 polihaloalquilo C1-6, arilo o Het; W es arilo o Het; R6 es hidrogeno; arilo; Het; cicloalquilo C3-7 sustituido opcionalmente con alquilo C1-6; o alquilo C1-6 sustituido opcionalmente con cicloalquilo C3-7, arilo o con Het; R7 es arilo; Het; cicloalquilo C3-7 sustituido opcionalmente con alquilo C1-6; o alquilo C1-6 sustituido opcionalmente con cicloalquilo C3-7, arilo o con Het; arilo es fenilo o naftilo, cada uno sustituido opcionalmente con 1-3 sustituyentes; Het es un anillo heterocíclico saturado, parcialmente no saturado o completamente no saturado de 5 o 6 miembros que contiene 1-4 heteroátomos, cada uno seleccionado independientemente de N, O o S y sustituido opcionalmente con 1-3 sustituyentes; composiciones farmacéuticas que contienen compuestos (1) y procesos para preparar compuestos (1). También se proporcionan combinaciones biodisponibles de los inhibidores de VHC de formula (i) con ritonavir.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05107070 | 2005-07-29 | ||
EP06101279 | 2006-02-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR055360A1 true AR055360A1 (es) | 2007-08-22 |
Family
ID=37103015
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060103305A AR055360A1 (es) | 2005-07-29 | 2006-07-28 | Inhibidores macrociclicos del virus de la hepatitis c |
Country Status (18)
Country | Link |
---|---|
US (1) | US7666834B2 (es) |
EP (1) | EP1919898B1 (es) |
JP (1) | JP5230414B2 (es) |
KR (1) | KR101381387B1 (es) |
CN (1) | CN101273027B (es) |
AR (1) | AR055360A1 (es) |
AT (1) | ATE496908T1 (es) |
AU (1) | AU2006274861B2 (es) |
BR (1) | BRPI0614242A2 (es) |
CA (1) | CA2617096C (es) |
DE (1) | DE602006019883D1 (es) |
DK (1) | DK1919898T3 (es) |
EA (1) | EA014293B1 (es) |
MY (1) | MY144607A (es) |
PL (1) | PL1919898T3 (es) |
SI (1) | SI1919898T1 (es) |
TW (1) | TWI375670B (es) |
WO (1) | WO2007014922A1 (es) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
ES2336009T3 (es) | 2004-01-30 | 2010-04-07 | Medivir Ab | Inhibidores de la ns-3 serina proteasa del vhc. |
PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
DK1912997T3 (da) * | 2005-07-29 | 2012-01-02 | Tibotec Pharm Ltd | Makrocycliske inhibitorer af hepatitis C virus |
WO2007014924A1 (en) | 2005-07-29 | 2007-02-08 | Tibotec Pharmaceuticals Ltd. | Macrocyclic inhibitors of hepatitis c virus |
JO2768B1 (en) * | 2005-07-29 | 2014-03-15 | تيبوتيك فارماسيوتيكالز ليمتد | Large cyclic inhibitors of hepatitis C virus |
KR20080056295A (ko) | 2005-10-11 | 2008-06-20 | 인터뮨, 인크. | C형 간염 바이러스 복제를 억제하기 위한 화합물 및 방법 |
US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
RU2008152171A (ru) | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
JP2009542698A (ja) * | 2006-07-07 | 2009-12-03 | ギリアード サイエンシーズ, インコーポレイテッド | 抗ウイルスホスフィナート化合物 |
EP2049474B1 (en) | 2006-07-11 | 2015-11-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2008096002A1 (en) * | 2007-02-08 | 2008-08-14 | Tibotec Pharmaceuticals Ltd. | Hcv inhibiting macrocyclic phosphonates and amidophosphates |
JP5554570B2 (ja) * | 2007-02-08 | 2014-07-23 | ヤンセン・アールアンドデイ・アイルランド | Hcv阻害大環状フェニルカルバメート |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
EP2185539A4 (en) * | 2007-08-03 | 2011-07-20 | Boehringer Ingelheim Int | VIRAL POLYMERASE INHIBITORS |
EP2188274A4 (en) | 2007-08-03 | 2011-05-25 | Boehringer Ingelheim Int | VIRAL POLYMERASE HEMMER |
US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
US8426360B2 (en) * | 2007-11-13 | 2013-04-23 | Enanta Pharmaceuticals, Inc. | Carbocyclic oxime hepatitis C virus serine protease inhibitors |
WO2009070692A1 (en) | 2007-11-29 | 2009-06-04 | Enanta Pharmaceuticals, Inc. | C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors |
US8476257B2 (en) | 2007-12-19 | 2013-07-02 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US8283309B2 (en) | 2007-12-20 | 2012-10-09 | Enanta Pharmaceuticals, Inc. | Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors |
US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
EP2268619A4 (en) | 2008-03-20 | 2012-04-04 | Enanta Pharm Inc | FLUORINATED MACROCYCLIC COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS |
US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2009148923A1 (en) | 2008-05-29 | 2009-12-10 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
KR20110098779A (ko) * | 2008-12-03 | 2011-09-01 | 프레시디오 파마슈티칼스, 인코포레이티드 | Hcv ns5a의 억제제 |
US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2376514A2 (en) | 2008-12-23 | 2011-10-19 | Pharmasset, Inc. | Nucleoside analogs |
MX2011006891A (es) | 2008-12-23 | 2011-10-06 | Pharmasset Inc | Fosforamidatos de nucleosidos. |
NZ593647A (en) | 2008-12-23 | 2013-08-30 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
EP2417134B1 (en) | 2009-04-08 | 2017-05-17 | Idenix Pharmaceuticals LLC. | Macrocyclic serine protease inhibitors |
TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
WO2011017389A1 (en) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
AU2011235112B2 (en) | 2010-03-31 | 2015-07-09 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
JP5872539B2 (ja) | 2010-03-31 | 2016-03-01 | ギリアド ファーマセット エルエルシー | プリンヌクレオシドホスホルアミダート |
US8822520B2 (en) | 2010-09-22 | 2014-09-02 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic HCV inhibitors |
AU2011336632B2 (en) | 2010-11-30 | 2015-09-03 | Gilead Pharmasset Llc | Compounds |
AR085352A1 (es) | 2011-02-10 | 2013-09-25 | Idenix Pharmaceuticals Inc | Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
NZ623396A (en) | 2011-09-16 | 2016-07-29 | Gilead Pharmasset Llc | Methods for treating hcv |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
JP6154474B2 (ja) | 2012-10-19 | 2017-06-28 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤 |
US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2014070974A1 (en) | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
LT2950786T (lt) | 2013-01-31 | 2020-03-10 | Gilead Pharmasset Llc | Dviejų antivirusinių junginių preparatų kompozicija |
WO2014137869A1 (en) | 2013-03-07 | 2014-09-12 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
NZ716840A (en) | 2013-08-27 | 2017-06-30 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
CN108191667B (zh) * | 2018-01-04 | 2021-03-26 | 利尔化学股份有限公司 | 2-硝基-4-三氟甲基苯甲酸甲酯的制备方法 |
CN114634422A (zh) * | 2022-03-14 | 2022-06-17 | 河北中科金辉药业有限公司 | 一种二硝托胺的制备方法 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69334250D1 (de) | 1992-12-29 | 2009-01-29 | Abbott Lab | Verfahren und Intermediate zur Herstellung von retroviralen Proteasehemmern |
IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
US5559158A (en) | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
IL111991A (en) | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
CZ298463B6 (cs) | 1996-04-23 | 2007-10-10 | Vertex Pharmaceuticals Incorporated | Deriváty mocoviny pro použití jako inhibitory IMPDH enzymu a farmaceutické prostredky, které je obsahují |
PL194025B1 (pl) | 1996-10-18 | 2007-04-30 | Vertex Pharma | Inhibitory proteaz serynowych, a zwłaszcza proteazy wirusa NS3 zapalenia wątroby C, kompozycja farmaceutyczna i zastosowanie inhibitorów proteaz serynowych |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
DK0966465T3 (da) | 1997-03-14 | 2003-10-20 | Vertex Pharma | Inhibitorer af IMPDH-enzymer |
ES2234144T3 (es) | 1997-08-11 | 2005-06-16 | Boehringer Ingelheim (Canada) Ltd. | Analogos de peptidos inhibidores de la hepatitis c. |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
ES2405316T3 (es) | 1999-03-19 | 2013-05-30 | Vertex Pharmaceuticals Incorporated | Inhibidores de la enzima IMPDH |
UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
US6867185B2 (en) * | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
NZ561851A (en) | 2002-04-11 | 2009-05-31 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis C virus NS3 - NS4 protease |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
US20050075279A1 (en) * | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
KR100940619B1 (ko) | 2003-02-07 | 2010-02-05 | 이난타 파마슈티칼스, 인코포레이티드 | 마크로사이클릭 씨형 간염 세린 단백효소 억제제 |
ES2386161T3 (es) * | 2003-04-16 | 2012-08-10 | Bristol-Myers Squibb Company | Proceso para separar una mezcla de enantiómeros de éster alquílico usando una enzima |
US7125845B2 (en) * | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
MXPA06003141A (es) * | 2003-09-22 | 2006-06-05 | Boehringer Ingelheim Int | Peptidos macrociclicos activos contra el virus de la hepatitis c. |
PL1680137T3 (pl) * | 2003-10-14 | 2013-04-30 | F Hoffmann La Roche Ltd | Makrocykliczny kwas karboksylowy i związek acylosulfonamidowy jako inhibitor replikacji HCV |
ES2336009T3 (es) | 2004-01-30 | 2010-04-07 | Medivir Ab | Inhibidores de la ns-3 serina proteasa del vhc. |
WO2005095403A2 (en) * | 2004-03-30 | 2005-10-13 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
PL1919904T3 (pl) * | 2005-07-29 | 2014-06-30 | Janssen R&D Ireland | Makrocykliczne inhibitory wirusa zapalenia wątroby typu C |
PE20070211A1 (es) * | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
DK1912997T3 (da) * | 2005-07-29 | 2012-01-02 | Tibotec Pharm Ltd | Makrocycliske inhibitorer af hepatitis C virus |
US7700552B2 (en) * | 2005-07-29 | 2010-04-20 | Medivir Ab | Macrocyclic inhibitors of hepatitis C virus |
MY144895A (en) * | 2005-07-29 | 2011-11-30 | Tibotec Pharm Ltd | Macrocylic inhibitors of hepatitis c virus |
-
2006
- 2006-07-28 DK DK06778069.2T patent/DK1919898T3/da active
- 2006-07-28 AT AT06778069T patent/ATE496908T1/de not_active IP Right Cessation
- 2006-07-28 AR ARP060103305A patent/AR055360A1/es unknown
- 2006-07-28 DE DE602006019883T patent/DE602006019883D1/de active Active
- 2006-07-28 AU AU2006274861A patent/AU2006274861B2/en not_active Ceased
- 2006-07-28 JP JP2008523378A patent/JP5230414B2/ja not_active Expired - Fee Related
- 2006-07-28 TW TW095127584A patent/TWI375670B/zh not_active IP Right Cessation
- 2006-07-28 PL PL06778069T patent/PL1919898T3/pl unknown
- 2006-07-28 US US11/995,827 patent/US7666834B2/en not_active Expired - Fee Related
- 2006-07-28 KR KR1020087004541A patent/KR101381387B1/ko not_active IP Right Cessation
- 2006-07-28 CA CA2617096A patent/CA2617096C/en not_active Expired - Fee Related
- 2006-07-28 CN CN200680035412.2A patent/CN101273027B/zh not_active Expired - Fee Related
- 2006-07-28 MY MYPI20063664A patent/MY144607A/en unknown
- 2006-07-28 EP EP06778069A patent/EP1919898B1/en active Active
- 2006-07-28 SI SI200630977T patent/SI1919898T1/sl unknown
- 2006-07-28 WO PCT/EP2006/064816 patent/WO2007014922A1/en active Application Filing
- 2006-07-28 EA EA200800477A patent/EA014293B1/ru not_active IP Right Cessation
- 2006-07-28 BR BRPI0614242-7A patent/BRPI0614242A2/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EA014293B1 (ru) | 2010-10-29 |
TW200740775A (en) | 2007-11-01 |
DE602006019883D1 (de) | 2011-03-10 |
EP1919898A1 (en) | 2008-05-14 |
KR20080039938A (ko) | 2008-05-07 |
PL1919898T3 (pl) | 2011-06-30 |
JP2009502885A (ja) | 2009-01-29 |
US7666834B2 (en) | 2010-02-23 |
EA200800477A1 (ru) | 2008-08-29 |
ATE496908T1 (de) | 2011-02-15 |
CA2617096C (en) | 2013-12-24 |
WO2007014922A1 (en) | 2007-02-08 |
JP5230414B2 (ja) | 2013-07-10 |
CA2617096A1 (en) | 2007-02-08 |
US20090105302A1 (en) | 2009-04-23 |
CN101273027B (zh) | 2015-12-02 |
SI1919898T1 (sl) | 2011-05-31 |
KR101381387B1 (ko) | 2014-04-11 |
MY144607A (en) | 2011-10-14 |
BRPI0614242A2 (pt) | 2011-03-15 |
AU2006274861B2 (en) | 2012-11-08 |
CN101273027A (zh) | 2008-09-24 |
EP1919898B1 (en) | 2011-01-26 |
TWI375670B (en) | 2012-11-01 |
DK1919898T3 (da) | 2011-05-02 |
AU2006274861A1 (en) | 2007-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR055360A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
AR055359A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
AR054882A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
TW200800949A (en) | Macrocylic inhibitors of hepatitis C virus | |
EA200970493A1 (ru) | Макроциклические ингибиторы вируса гепатита с | |
AR057704A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c, composicion farmaceutica y proceso de preparacion del compuesto | |
PE20070189A1 (es) | COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA | |
TW200745061A (en) | Macrocylic inhibitors of hepatitis C virus | |
CO6251247A2 (es) | Imidazoquinolinas con propiedades inmuno-moduladoras | |
PE20081510A1 (es) | Derivados de dihidropiridina como inhibidores de la proteina quinasa | |
PE20080072A1 (es) | Compuestos heterociclicos como inhibidores de proteasas serinas | |
AR072166A1 (es) | Derivado de piperidina y su uso como inhibidor de renina superior | |
CO5640155A2 (es) | Derivados de pirido[2,1-a]isoquinolina como inhibidores de la dpp-iv | |
CR8505A (es) | Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad | |
PE20120229A1 (es) | Compuestos heterociclicos como inhibidores de proteasa aspartica | |
CO6251271A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
PE20130647A1 (es) | Indoles | |
AR049951A1 (es) | Derivados de ftalazina como inhibidores de parp | |
PE20080841A1 (es) | Derivados de quinazolinona e isoquinolinona y su uso para el tratamiento o prevencion de trastornos relacionados con el estres o la depresion | |
PE20090601A1 (es) | Derivados de piridin-il-oxi-piridinas como inhibidores de alk5 | |
MX2010000658A (es) | Derivados de pirimidina 934. | |
AR046200A1 (es) | Derivados de pirazina y su uso farmaceutico. procesos de preparacion y composiciones farmaceuticas | |
AR074758A1 (es) | Compuestos macrociclicos antivirales | |
PE20041078A1 (es) | Derivados heterociclicos inhibidores de la elastasa leucocitica humana (elh) | |
AR053141A1 (es) | Imidazoles sustituidos con heterociclilamida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |